SILO: 143% | Silo Pharma Obtains Exclusive Global License To Develop, Manufacture, And Commercialize Its Alzheimer's Drug
GOVX: 35% | Roth MKM Initiates Coverage On Geovax Labs with Buy Rating, Announces Price Target of $20
CFB: -12% | CrossFirst Bankshares shares are trading lower. The company reported Q2 financial results.
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 4/15/2025 | $18.00 → $14.00 | Buy | D. Boral Capital | |
| 4/15/2025 | $15.00 → $8.50 | Buy | Alliance Global Partners | |
| 11/11/2024 | $15.00 | Buy | Alliance Global Partners | |
| 9/10/2024 | $21.00 | Neutral → Buy | Janney | |
| 7/16/2024 | $20.00 | Buy | ROTH MKM | |
| 2/21/2024 | Neutral | Janney | ||
| 1/24/2024 | $16.00 → $18.00 | Equal-Weight → Overweight | Stephens | |
| 1/5/2024 | $16.00 | Mkt Perform → Outperform | Raymond James |
Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a non-binding Letter of Intent ("LOI") with Allucent (US) LLC ("Allucent"), a global clinical research organization (CRO), to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subject
SARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Allucent, a global full-service clinical research organization (CRO), to support the Company's final preparations and planned submission of its investigational new drug application (IND) to the FDA for a Phase 1 clinical trial of its intranasal prophylactic SPC-15 as a treatment for PTSD. The Company currently expects to submit the IND in 2026 and commence its first-in-human (FIH) SPC-15 trial subsequent to FDA approval. "We believe that a partnership with All
Investment vehicle provides diversified exposure to real-world assets and expected to reduce portfolio volatility Strategic allocation aligns with Silo's objective of generating yield while maintaining a hedge against downside risk New York, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Alphaledger/Simplify Target 12% Distribution Fund LLC (the "Alphaledger T12 Fund") as a core component of its real-world asset (RWA) investment strategy on the Solana blockchain. This strategic allocation aligns with Silo's approac
D. Boral Capital reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $14.00 from $18.00 previously
Alliance Global Partners reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $8.50 from $15.00 previously
Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
424B5 - GeoVax Labs, Inc. (0000832489) (Filer)
8-K - GeoVax Labs, Inc. (0000832489) (Filer)
8-K - Silo Pharma, Inc. (0001514183) (Filer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin
Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci
Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology. Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development
Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was
LEAWOOD, Kan., April 22, 2025 (GLOBE NEWSWIRE) -- First Busey Corporation (NASDAQ:BUSE) reports first quarter results. Busey completed the transformative acquisition of CrossFirst Bankshares, Inc. on March 1, 2025, significantly impacting first quarter results and resetting the baseline for financial performance for future quarters in a multitude of positive ways. Net Income (Loss)Diluted EPSNet Interest Margin1ROAA1ROATCE1$(30.0) million$(0.44)3.16%(0.82)%(7.99)%$39.9 million (adj)2$0.57 (adj)23.08% (adj)21.09% (adj)210.64% (adj)2 MESSAGE FROM OUR CHAIRMAN & CEOThe transformative partnership between Busey and CrossFirst takes our organization to new heights, combining our growing c
CHAMPAIGN, Il. and LEAWOOD, Kan., March 03, 2025 (GLOBE NEWSWIRE) -- First Busey Corporation ("Busey") (NASDAQ:BUSE), the holding company for Busey Bank, announced today the completion of its acquisition by merger of CrossFirst Bankshares, Inc. ("CrossFirst") (NASDAQ:CFB), the holding company for CrossFirst Bank, effective March 1, 2025. The transaction was previously jointly announced on August 27, 2024. Busey will operate CrossFirst Bank as a separate banking subsidiary of Busey until it is merged with Busey Bank, which is expected to occur in June 2025. At the time of the bank merger, CrossFirst Bank's banking centers will become branches of Busey Bank and operate under the Busey brand
SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)
SC 13G/A - CROSSFIRST BANKSHARES, INC. (0001458412) (Subject)
SC 13G - Silo Pharma, Inc. (0001514183) (Subject)